Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

Orelabrutinib combined with rituximab (OR) therapy were used to assess the efficacy and safety for newly diagnosed Marginal zone cell lymphoma

Start Date23 Jun 2024

Sponsor / Collaborator

The First Affiliated Hospital of Xiamen University

[+8]

100 Clinical Results associated with Shanxi Province Cancer Hospital

0 Patents (Medical) associated with Shanxi Province Cancer Hospital

403

Literatures (Medical) associated with Shanxi Province Cancer Hospital

08 Sep 2024·Zhonghua bing li xue za zhi = Chinese journal of pathology

[Application value of immunohistochemistry INSM1 combined with periodic acid-Schiff stain double staining in glandular and neuroendocrine amphicrine carcinoma in the digestive tract].

Article

Author: Wang, J ; Xie, L W ; Bu, P ; Yang, X Q

01 Sep 2024·Nature Medicine

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial

Article

Author: Yang, Hao ; Hou, Zhiguo ; Qi, Yu ; Qin, Jianjun ; Zhang, Ruixiang ; Zhang, Yong ; Li, Bin ; Tan, Lijie ; Ni, Yunfeng ; Li, Yong ; Wang, Xiaoyuan ; Zhu, Wenqing ; Li, Lin ; Kang, Mingqiang ; Chen, Qixun ; Zhang, Chen ; Li, Hecheng ; Kang, Xiaozheng ; Lin, Jihong ; Zheng, Rongrong ; Tian, Hui ; Wang, Zhen ; Chen, Longqi ; Hao, Anlin ; Chen, Xiankai ; Fu, Junke ; Han, Yongtao ; Jiang, Hongjing ; Tian, Ziqiang ; He, Jie ; Wei, Li ; Zhang, Weiguo ; Liao, Yongde ; Chen, Yujie ; Jiang, Tao ; Xue, Liyan ; Li, Chengqiang ; Li, Yin ; Guo, Shiping ; Liu, Shuoyan ; Guo, Xiaofeng ; Li, Zhigang ; Ma, Jianqun ; Fu, Maoyong ; Dai, Tianyang ; Yang, Zhaoyang

AbstractRecent single-arm studies involving neoadjuvant camrelizumab, a PD-1 inhibitor, plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) have shown promising results. This multicenter, randomized, open-label phase 3 trial aimed to further assess the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy followed by adjuvant camrelizumab, compared to neoadjuvant chemotherapy alone. A total of 391 patients with resectable thoracic LA-ESCC (T1b-3N1-3M0 or T3N0M0) were stratified by clinical stage (I/II, III or IVA) and randomized in a 1:1:1 ratio to undergo two cycles of neoadjuvant therapy. Treatments included camrelizumab, albumin-bound paclitaxel and cisplatin (Cam+nab-TP group; n = 132); camrelizumab, paclitaxel and cisplatin (Cam+TP group; n = 130); and paclitaxel with cisplatin (TP group; n = 129), followed by surgical resection. Both the Cam+nab-TP and Cam+TP groups also received adjuvant camrelizumab. The dual primary endpoints were the rate of pathological complete response (pCR), as evaluated by a blind independent review committee, and event-free survival (EFS), as assessed by investigators. This study reports the final analysis of pCR rates. In the intention-to-treat population, the Cam+nab-TP and Cam+TP groups exhibited significantly higher pCR rates of 28.0% and 15.4%, respectively, compared to 4.7% in the TP group (Cam+nab-TP versus TP: difference 23.5%, 95% confidence interval (CI) 15.1–32.0, P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034). The study met its primary endpoint of pCR; however, EFS is not yet mature. The incidence of grade ≥3 treatment-related adverse events during neoadjuvant treatment was 34.1% for the Cam+nab-TP group, 29.2% for the Cam+TP group and 28.8% for the TP group; the postoperative complication rates were 34.2%, 38.8% and 32.0%, respectively. Neoadjuvant camrelizumab plus chemotherapy demonstrated superior pCR rates compared to chemotherapy alone for LA-ESCC, with a tolerable safety profile. Chinese Clinical Trial Registry identifier: ChiCTR2000040034.

01 Aug 2024·Annals of Hematology

Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China

Article

Author: Song, Yu-Qin ; Wang, Wei ; Wang, Shu-Ye ; Luo, Jian-Min ; Wang, Quan-Shun ; Shen, Jing ; O'Connor, O A ; Zhang, Wei ; Jing, Hong-Mei ; Cen, Xi-Nan ; Su, Li-Ping ; Liu, Li-Hong ; Zhang, Hui-Lai ; Liu, Ai-Chun ; Zhou, Dao-Bin ; Gao, Yu-Huan ; Wang, Jing-Wen ; He, Jian-Xia ; Su, Hang ; Liu, Hui ; Li, Zeng-Jun

In this prospective, multicenter, Phase 2 clinical trial (NCT02987244), patients with peripheral T-cell lymphomas (PTCLs) who had responded to first-line chemotherapy with cyclophosphamide, doxorubicin or epirubicin, vincristine or vindesine, etoposide, and prednisone (Chi-CHOEP) were treated by autologous stem cell transplantation (ASCT) or with chidamide maintenance or observation. A total of 85 patients received one of the following interventions: ASCT (n = 15), chidamide maintenance (n = 44), and observation (n = 26). estimated 3 PFS and OS rates were 85.6%, 80.8%, and 49.4% (P = 0.001). The two-year OS rates were 85.6%, 80.8%, and 69.0% (P = 0.075).The ASCT and chidamide maintenance groups had significantly better progression-free survival (PFS) than the observation group (P = 0.001, and P = 0.01, respectively). The overall survival (OS) differed significantly between the chidamide maintenance group and the observation group ( P = 0.041). The multivariate and propensity score matching analyses for PFS revealed better outcomes in the subjects in the chidamide maintenance than observation groups (P = 0.02). The ASCT and chidamide maintenance groups had significant survival advantages over the observation group. In the post-remission stage of the untreated PTCL patients, single-agent chidamide maintenance demonstrated superior PFS and better OS than observation. Our findings highlight the potential benefit of chidamide in this patient subset, warranting further investigation through larger prospective trials. Clinical trial registration: clinicaltrial.gov, NCT02987244. Registered 8 December 2016, http://www.clinicaltrials.gov/ct2/show/NCT02987244 .

100 Deals associated with Shanxi Province Cancer Hospital

100 Translational Medicine associated with Shanxi Province Cancer Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Shanxi Province Cancer Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 22 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing